RANI

Rani Therapeutics Holdings, Inc. Class A Common Stock (RANI) | Rumor.io

Rani Therapeutics Holdings

RANI

Attention (50-day avg)0%

Attention rank (50-day avg)#2,343

Bullish sentiment (50-day avg)96%

Price to earnings ratio-1.75

Market capitalization109M

Earnings per share-0.13

Dividend yield (TTM)—

Revenue (annual)1.6M

Net income (annual)-41M

Social

What share of all stock conversation is about RANI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

Aug 19

Rani Therapeutics Holdings, Inc. ($RANI) has been accumulating cash, with a strong cash position, and is expected to have a significant window to build a position in September-October.
The company has shown unusual and bullish price behavior, and some speculate that a significant announcement or news is in the works, which could be extremely bullish for the stock.
The retail sentiment for Rani Therapeutics is strongly bullish, driven by a mix of broader sector momentum and specific catalyst anticipation, with high sentiment scores and a focus on novel delivery methods and potential big-pharma licensing deals.

Generated by AI

Sentiment

Of the messages about RANI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% 0	100% +5.1	86.77% +0.48
Bearish	—	0% 0	0% -5.1	13.23% -0.48

Bullish· Jul 22

The company has reported strong Phase 1a clinical trial results for its oral obesity treatment, RT-114, with high bioequivalence and success with the RaniPill platform for oral delivery of obesity medication.
The CEO of Rani Therapeutics has recently purchased 35,000 shares on the open market, signaling strong executive confidence in the company's future pipeline and growth prospects.
The company's stock is experiencing a powerful short squeeze, driven by high short interest and a sudden surge in buy volume, with volume exploding past 5 million shares and pushing the stock up over 32%.

Bearish· Nov 7

Rani Therapeutics Holdings, Inc. ($RANI) may retrace to the mid-$1s due to its 400% return in a month being unsustainable.
The stock's recent drop may be attributed to market makers accumulating shares, rendering retail investors powerless over share price action.
$RANI's technical chart indicates it was highly overbought before falling, and it may drift lower until the next catalyst, such as the initiation of a Phase 1 trial.

Generated by AI

Topics

Of the messages about RANI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	3.99%
Technical Analysis	—	—	0%	28.92%
Analysts	—	—	0%	33.23%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0.04%
Macro	—	—	0%	33.82%

Announcements· Nov 6

Rani Therapeutics Holdings, Inc. announced a collaboration with Chugai Pharmaceutical Co. worth up to $1.085 billion for multiple high-value therapeutics.
The company completed a $60.3 million private placement led by Samsara BioCapital and appointed two new board members, extending its cash runway into 2028.
Rani Therapeutics plans to start the RT114 trial before the end of the year and has a robust pipeline with a large addressable market in the billions.

Technical Analysis· Nov 5

$RANI is setting up for a breakout, with a textbook S/D flip breakout setup and a potential range to $3.30+.
A break above 2.6 is seen as a bullish signal, with a potential target of $3.85, and a break below 2.6 could be a double top on the weekly chart.
$RANI has a bullish momentum, with a recent gain of +207% in two weeks, and is holding steady at $2.00 support, with resistance at $2.56-$3.00.

Generated by AI

Community

Of the messages about RANI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	75%	86.67%	8.15%
Newcomers	—	25%	13.33%	91.85%

Jul 22

The newcomer investors are focused on the promising Phase 1a clinical trial results for Rani Therapeutics' (RANI) oral obesity treatment, RT-114, which has shown high bioequivalence and success with the RaniPill platform.
The newcomers are also discussing the recent R&D collaboration agreement between Rani Therapeutics and PegBio Co. to co-develop metabolic and obesity therapies, as well as the CEO's insider buying, which signals strong executive confidence in the company's future pipeline and growth prospects.
The investors are speculating about the potential for a milestone payment from Chugai, which could be triggered by the completion of the phase 1 clinical trial for RT-114 on December 1st, and the potential for a larger milestone payment based on the results of the trial.

Generated by AI

SAN JOSE, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today announced that the company’s management team will participate in the upcoming September conferences. 10th Annual Best Ideas Growth (BIG10) Conference hosted by Lake Street Capital MarketsDate: Thursday, September 10, 2026 Format: 1x1 MeetingsLocation: New York, NY H.C. Wainwright 28th Annual Global Investment C

21d agoca.finance.yahoo.com

H.C. Wainwright reiterates Rani Therapeutics stock rating at buy

1mo agoInvesting.com

This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tues

1mo agoBenzinga

Rani Therapeutics Expands Oral Biologics Push With Obesity, Immunology Pipeline

Rani Therapeutics (NASDAQ:RANI) outlined its strategy to expand the use of its RaniPill oral biologic-delivery platform through a mix of technology partnerships, selectively licensed product programs and investments in manufacturing capacity. Chief Executive Officer Talat Imran described the clinic

1mo agoYahoo Finance

Rani Therapeutics Holdings earnings beat by $0.01, revenue topped estimates

1mo agoInvesting.com

Also Discussed

Investors talking about RANI also mention

#	Name	Attention
1	Intensity Therapeutics, Inc.INTS	0%0
2	Scienture Holdings, Inc.SCNX	0%0
3	Vsee Health Inc.VSEE	0%0
4	Cambium Networks CorporationCMBM	0%0
5	VIVK - Vivakor, Inc.	——
6	MultiSensor AI Holdings Inc.MSAI	0%0
7	BeneficientBENF	0.01%0
8	Safe & Green Holdings Corp.SGBX	0%0
9	Modular Medical, Inc.MODD	0%+0
10	Genenta Science S.p.A. Sponsored ADRGNTA	0%0

Rani Therapeutics Holdings, Inc. Class A Common Stock

Healthcare
Biotechnology

Rani Therapeutics Holdings, Inc. Class A Common Stock represents equity in Rani Therapeutics, a clinical-stage biotherapeutics company focused on oral delivery technologies for biologics and other drugs. The company’s core product is the RaniPill capsule, a proprietary platform designed to administer large-molecule therapies through the gastrointestinal tract, offering an alternative to injections and infusions. Rani Therapeutics develops this technology for use across multiple therapeutic areas, including peptides, proteins, antibodies, and oligonucleotides. Its business is centered on advancing drug-delivery solutions that may support patients, physicians, and healthcare systems by making biologic administration more convenient. The company operates in the biotechnology and health care life sciences sectors, where oral delivery platforms are an important area of innovation.

Website

Location

2051 Ringwood Avenue

San Jose, CA, 95131

United States

Social

What share of all stock conversation is about RANI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

Aug 19

Rani Therapeutics Holdings, Inc. ($RANI) has been accumulating cash, with a strong cash position, and is expected to have a significant window to build a position in September-October.
The company has shown unusual and bullish price behavior, and some speculate that a significant announcement or news is in the works, which could be extremely bullish for the stock.
The retail sentiment for Rani Therapeutics is strongly bullish, driven by a mix of broader sector momentum and specific catalyst anticipation, with high sentiment scores and a focus on novel delivery methods and potential big-pharma licensing deals.

Generated by AI

Sentiment

Of the messages about RANI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% 0	100% +5.1	86.77% +0.48
Bearish	—	0% 0	0% -5.1	13.23% -0.48

Bullish· Jul 22

The company has reported strong Phase 1a clinical trial results for its oral obesity treatment, RT-114, with high bioequivalence and success with the RaniPill platform for oral delivery of obesity medication.
The CEO of Rani Therapeutics has recently purchased 35,000 shares on the open market, signaling strong executive confidence in the company's future pipeline and growth prospects.
The company's stock is experiencing a powerful short squeeze, driven by high short interest and a sudden surge in buy volume, with volume exploding past 5 million shares and pushing the stock up over 32%.

Bearish· Nov 7

Rani Therapeutics Holdings, Inc. ($RANI) may retrace to the mid-$1s due to its 400% return in a month being unsustainable.
The stock's recent drop may be attributed to market makers accumulating shares, rendering retail investors powerless over share price action.
$RANI's technical chart indicates it was highly overbought before falling, and it may drift lower until the next catalyst, such as the initiation of a Phase 1 trial.

Generated by AI

Topics

Of the messages about RANI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	3.99%
Technical Analysis	—	—	0%	28.92%
Analysts	—	—	0%	33.23%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0.04%
Macro	—	—	0%	33.82%

Announcements· Nov 6

Rani Therapeutics Holdings, Inc. announced a collaboration with Chugai Pharmaceutical Co. worth up to $1.085 billion for multiple high-value therapeutics.
The company completed a $60.3 million private placement led by Samsara BioCapital and appointed two new board members, extending its cash runway into 2028.
Rani Therapeutics plans to start the RT114 trial before the end of the year and has a robust pipeline with a large addressable market in the billions.

Technical Analysis· Nov 5

$RANI is setting up for a breakout, with a textbook S/D flip breakout setup and a potential range to $3.30+.
A break above 2.6 is seen as a bullish signal, with a potential target of $3.85, and a break below 2.6 could be a double top on the weekly chart.
$RANI has a bullish momentum, with a recent gain of +207% in two weeks, and is holding steady at $2.00 support, with resistance at $2.56-$3.00.

Generated by AI

Community

Of the messages about RANI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	75%	86.67%	8.15%
Newcomers	—	25%	13.33%	91.85%

Jul 22

The newcomer investors are focused on the promising Phase 1a clinical trial results for Rani Therapeutics' (RANI) oral obesity treatment, RT-114, which has shown high bioequivalence and success with the RaniPill platform.
The newcomers are also discussing the recent R&D collaboration agreement between Rani Therapeutics and PegBio Co. to co-develop metabolic and obesity therapies, as well as the CEO's insider buying, which signals strong executive confidence in the company's future pipeline and growth prospects.
The investors are speculating about the potential for a milestone payment from Chugai, which could be triggered by the completion of the phase 1 clinical trial for RT-114 on December 1st, and the potential for a larger milestone payment based on the results of the trial.

Generated by AI

Rani Therapeutics Holdings

Social

Aug 19

Sentiment

Bullish· Jul 22

Bearish· Nov 7

Topics

Announcements· Nov 6

Technical Analysis· Nov 5

Community

Jul 22

News

Rani Therapeutics at H.C. Wainwright: oral biologics gain traction

Rani Therapeutics to Participate in Upcoming September Conferences

H.C. Wainwright reiterates Rani Therapeutics stock rating at buy

This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tues

Rani Therapeutics Expands Oral Biologics Push With Obesity, Immunology Pipeline

Rani Therapeutics Holdings earnings beat by $0.01, revenue topped estimates

Also Discussed

Rani Therapeutics Holdings, Inc. Class A Common Stock

Company Information

Location

Social

Aug 19

Sentiment

Bullish· Jul 22

Bearish· Nov 7

Topics

Announcements· Nov 6

Technical Analysis· Nov 5

Community

Jul 22

News

Rani Therapeutics at H.C. Wainwright: oral biologics gain traction

Rani Therapeutics to Participate in Upcoming September Conferences

H.C. Wainwright reiterates Rani Therapeutics stock rating at buy

This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tues

Rani Therapeutics Expands Oral Biologics Push With Obesity, Immunology Pipeline

Rani Therapeutics Holdings earnings beat by $0.01, revenue topped estimates

Also Discussed